This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
by Zacks Equity Research
Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
Emergent (EBS) Q4 Earnings, Revenues Surpass Estimates
by Zacks Equity Research
Emergent (EBS) rides high on both earnings and a revenue beat in Q4.
Emergent Biosolutions (EBS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 22.95% and 0.63%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Emergent Biosolutions (EBS) Q4 Earnings Expected to Decline
by Zacks Equity Research
Emergent Biosolutions (EBS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Emergent (EBS) Up on '19 View, Posts Preliminary '18 Results
by Zacks Equity Research
Emergent (EBS) provides preliminary results for 2018 and guidance for 2019. The results exceed estimates.
Emergent (EBS) CEO Abdun Nabi to Retire, Kramer to Succeed
by Zacks Equity Research
Emergent (EBS) names Robert G. Kramer, Sr. as its next chief executive officer, who will assume office from Apr 1, 2019 onward. He will succeed the incumbent CEO Daniel J. Abdun-Nabi.
Emergent (EBS) Files Application for Emergency Use of NuThrax
by Zacks Equity Research
Emergent (EBS) submits an application to the FDA for the emergency use of its anthrax vaccine candidate, NuThrax.
Emergent Biosolutions (EBS) Up 14.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Emergent Biosolutions (EBS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint
by Zacks Equity Research
Emergent BioSolutions (EBS) and partner Valneva present positive data from an early-stage study on the Zika vaccine candidate, VLA1601.
Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates
by Zacks Equity Research
Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.
Emergent Biosolutions (EBS) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of -11.29% and -7.73%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Exelixis (EXEL) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Exelixis' (EXEL) third-quarter results are expected to benefit from Cabometyx performance and other pipeline updates.
What's in Store for Sangamo (SGMO) This Earnings Season?
by Zacks Equity Research
On Sangamo's (SGMO) Q3 2018 conference call, investor focus will be on the company's progress with its genome editing and gene regulation technology platform.
What's in the Cards for Geron (GERN) This Earnings Season?
by Zacks Equity Research
In a major setback to Geron (GERN), J&J terminates collaboration for development of its sole pipeline candidate, imetelstat. Investor focus to remain on path forward for imetelstat.
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin (AMRN) is scheduled to release third-quarter earnings on Nov 1.
Emergent Biosolutions (EBS) Q3 Earnings Preview: What's Shaping Up?
by Zacks Equity Research
Emergent Biosolutions (EBS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EBS or ALKS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
EBS vs. ALKS: Which Stock Is the Better Value Option?
Emergent Completes Acquisition of Narcan Maker Adapt Pharma
by Zacks Equity Research
Emergent (EBS) wraps up the buyout of Adapt Pharma for $735 million. This strategic move will add the latter's popular Narcan nasal spray to its portfolio.
Vaxart's Flu Vaccine Superior to Sanofi's Fluzone, Shares Up
by Zacks Equity Research
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
Emergent (EBS) to Buy Narcan Maker Adapt Pharma for $735M
by Zacks Equity Research
Emergent (EBS) inks a deal to buy Adapt Pharma. This move will add the latter's popular Narcan nasal spray to its portfolio.
Emergent (EBS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) rides high on earnings as well as revenue beat in Q2.
Emergent Biosolutions (EBS) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Emergent Biosolutions (EBS) delivered earnings and revenue surprises of 11.46% and 5.21%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
EBS vs. NEO: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
EBS vs. NEO: Which Stock Is the Better Value Option?
by Zacks Equity Research
EBS vs. NEO: Which Stock Is the Better Value Option?
What Lies Ahead for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.